Search
- Jun 7, 2023
Talking oncology targets (EGFR, FLT3, B7H4 and more) with Cullinan Oncology
Cullinan Oncology CEO Nadim Ahmed walks us through the oncology targets the company is focused on and discusses recent ASCO data.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A